Designer steroids

Handbook of Experimental Pharmacology

Volumn 195, Issue , 2010, Pages 155-185

  Kazlauskas, Ray ^a  

^a NATIONAL MEASUREMENT INSTITUTE   (Australia)

Author keywords

Anabolic steroids; BALCO; Designer steroids; Supplements; WADA

Indexed keywords

4 CHLORO 17BETA HYDROXY 17 METHYLANDROSTA 1,4 DIEN 3 ONE; 4 HYDROXYTESTOSTERONE; ANABOLIC AGENT; ANDROST 1 ENE 3,17 DIONE; ANDROSTENEDIOL; BOLANDIOL; BOLASTERONE; BOLDENONE; CALUSTERONE; CLOSTEBOL; DANAZOL; DESIGNER DRUG; DROSTANOLONE; ETHYLESTRENOL; FLUOXYMESTERONE; FORMEBOLONE; FURAZABOL; GESTRINONE; MESTANOLONE; MESTEROLONE; METANDIENONE; METENOLONE; METHANDRIOL; METHYLDIENOLONE; METHYLTESTOSTERONE; METRIBOLONE; MIBOLERONE; NANDROLONE; STEROID; UNINDEXED DRUG;

ATHLETE; DIET SUPPLEMENTATION; DOPING; DRUG DETERMINATION; DRUG STRUCTURE; HUMAN; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; PRIORITY JOURNAL; REVIEW; TANDEM MASS SPECTROMETRY; ANIMAL; CHEMISTRY; MASS SPECTROMETRY; METHODOLOGY; SYNTHESIS;

ANABOLIC AGENTS; ANIMALS; CHROMATOGRAPHY, LIQUID; DESIGNER DRUGS; DIETARY SUPPLEMENTS; DOPING IN SPORTS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MASS SPECTROMETRY; STEROIDS;

EID: 77449150692     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-79088-4_7     Document Type: Review

References (63)

1. Albanese AA (1969) Nutritional and metabolic effects of anabolic steroids and corticosteroids. J Am Med Wom Assoc 24(1):42-51
2. Albanese AA, Lorenze EJ, Orto LA, Wein EH (1968) Nutritional and metabolic effects of some newer steroids V. Norbolethone. NY State J Med 68(18):2392-2406
3. Articles (2005), http://sport.guardian.co.uk/athletics/story/0, 1605761,00.html; http://www.anti-doping.ee/failikataloog/ East%20Germany%20doping%20victims...28.04.05.pdf. sighted Nov 2007
4. ASADA (2006), http://www.comlaw.gov.au/ComLaw/Legislation/Act1.nsf/0/ C3977FDB55132A3F-CA25713000066A85/$file/006-2006.pdf. sighted April 2008
5. BALCO articles (2006), http://www.ergogenics.org/120.html#9b; http://www.sfgate.com/cgi-bin/ article.cgi?f=/c/a/2006/08/05/MNG21KBVGA1.DTL. sighted April 2008
6. Bovee TFH, Lommerse JPM, Peijnenburg Ad ACM, Fernandes EA, Nielsen MWF (2008) A new highly androgen specific yeast biosensor, enabling optimisation of (Q) SAR model approaches. J Steroid Biochem Mol Biol J Steroid Biochem Mol Biol 108(1-2):121-131
7. Bowers LD (1997) Analytical advances in detection of performance- enhancing compounds. Clin Chem 43(7):1299-1304
8. Catlin DH, Ahrens BD, Kucherova Y (2002) Detection of norbolethone, an anabolic steroid never marketed, in athletes' urine. Rapid Commun Mass Spectrom 16:1273-1275
9. Catlin DH, Sekera MH, Ahrens BD, Starcevic B, Chang Y-C, Hatton CK (2004) Tetrahydrogestrinone: discovery, synthesis, and detection in urine. Rapid Commun Mass Spectrom 18:1245-1249
10. Corrigan B, Kazlauskas R (2003) Medication use in athletes selected for doping control at the Sydney Olympics. Clin J Sports Med 13:33-40
11. Covey DF, Hood WF (1981) Enzyme-generated intermediates derived from 4-androstene-3, 6, 17-triene and 1, 4, 6-androstatriene-3, 17-dione cause a time-dependent decrease in human placental aromatase activity. Endocrinology 108:1597-1599
12. Death AK, McGrath KCY, Kazlauskas R, Handelsman DJ (2004) Tetrahydrogestrinone (THG) is a potent androgen and progestin. J Clin Endocrinol Metab 89(5):2498-2500
13. Desaulles PA, Schärr B (1967) Properties of a new highly active anabolic steroid CIBA 36,644-Ba. Proc Int Congr Horm Steroids 32:541-547
14. Dorfman RI (1968) Relative potency of steroids on the rat levator ani muscle. J Am Med Wom Assoc 23(8):725-733
15. Dörner G (1965) 4-Chlor-D1-Methyltestosteron (Oral-Turinabol), ein neues oral wirksames Anabolikum. Dtsch Gesundheitswes 20:670-694
16. eMIMS Version 5.00.0248, MIMS, CMPMedica Australia PTY,LTD, ACN 050 695 157
17. Fourcroy J (2006) Designer steroids: past, present and future. Curr Opin Endocrinol Diabet 13:306-309
18. Friedel A, Geyer H, Kamber M, Laudenbach-Leschowsky U, Schänzer W, Thevis M, Vollmer G, Zierau O, Diel P (2006) Tetrahydrogestrinone is a potent but unselective binding steroid and affects glucocorticoid signalling in the liver. Toxicol Lett 164(1):16-23
19. Gaido KW, Leonard LS, Lovell S, Gould JC, Babai D, Portier CJ, McDonnell DP (1997) Evaluation of chemicals with endocrine modulating activity in a yeast-based steroid hormone receptor gene transcription assay. Toxicol Appl Pharmacol 143:205-212
20. Georgakopoulos CG, Vonaparti A, Stamou M, Kiousi P, Lyris E, Angelis YS, Tsoupras G, Wuest B, Niesen MWF, Panderi I, Koupparis M (2007) Preventive doping control analysis: liquid and gas chromatography time-of-flight mass spectrometry for detection of designer steroids. Rapid Commun Mass Spectrom 21:2439-2446
21. Geyer H, Parr MK, Mareck U, Reinhart U, Schrader Y, Schänzer W (2004) Analysis of nonhormonal nutritional supplements for anabolic-androgenic steroids - results of an international study. Int J Sports Med 25(2):124-129
22. Horning S, Donike M (1994) High-resolution GC/MS. In: Donike et al (ed) Recent advances in doping analysis, Proceedings of the 11th cologne workshop on dope analysis 7th to 12th March 1993, pp 155-162
23. Joska J, Fajkoš J, Šorm F (1968) On steroids. CXVII. 5, 7-cyclosteroids. III. 5, 7-cyclosteroid androgen analogues. Collect Czechoslov Chem Commun 33:3342-3355
24. Kaneko H, Nakamura K, Yamato Y, Kurokawa M (1969) Synthesis and structure-activity relationships of 7a-alkylthioandrostanes. Chem Pharm Bull 17(1):11-22
25. Kazlauskas R (2006) Miscellaneous projects in sports drug testing at the National Measurement Institute, Australia. In: Schänzer et al (ed) Recent advances in doping analysis (14). Proceedings of the Manfred Donike Workshop, 24th Cologne Workshop on Dope Analysis 4th to 9th June 2006, pp 129-140
26. Khripach VA, Zhabinskii VN, Kuchto AI, Zhiburtovich YY, Fando GP, Lyakhov AS, Govorova AA, Groen MB, van der Louw J, de Groot A (2004) Synthesis of 13, 14-secotestosterone derivatives. Steroids 69:501-509
27. Khripach VA, Zhabinskii VN, Fando GP, Kuchto AI, Khripach NB, Groen MB, van der Louw J, de Groot A (2006) A new type of steroids with a cyclobutane fragment in the AB-ring moiety. Steroids 71:445-449
28. Klimstra PD (1969) Androgenic and anabolic steroids. Intra-Sci Chem Rep 3(1-2):83-103
29. Kochakian CD (1950) Comparison of protein anabolic property of various androgens in the castrated rat. Am J Physiol 160:53-61
30. Kochakian CD (1976) Anabolic-androgenic steroids. In: Kochakian CD (ed) Metabolic effects of anabolic-androgenic steroids in experimental animals, vol 43. Springer, Berlin, pp 5-44
31. Little K (1970) Interaction between catabolic and anabolic steroids. Curr Therapeut Res 12 (10):658-676
32. McRobb L, Handelsman DJ, Kazlauskas R, Wilkinson S, McLeod MD, Heather AK (2008) Structure-activity relationships of synthetic progestins in a yeast-based in vitro androgen bioassay. J Steroid Biochem Mol Biol . doi:10.1016/j.jsbmb.2007.10.008, Feb 12
33. Miyake T, Takeda K (1967) Epithioandrostanol, a new type of anti-estrogen. Proc Int Congr Horm Steroids 2nd, Meeting Date 1966, pp 616-627
34. Miyake T, Komeno T, Takeda K (1969) 2α, 3α -Epi thio-5α -androstan-17β -ol and related compounds. III. Structure-activity relations. Shionogi Kenkyusho Nenpo 19:39-50
35. Munoz-Guerra J, Carreras D, Soriano C, Rodriguez C, Rodriguez AF (1977) Use of ion trap (GC- MS-MS) mass spectrometry for detection and confirmation of anabolic substances at low concentration levels in doping analysis. In: Schänzer et al (ed) Recent advances in doping analysis (5), Proceedings of the Manfred Donike workshop 15th cologne workshop on dope analysis 23rd to 28th February 1997, pp 169-184
36. Nielen MWF, Bovee TFH, van Engelen MC, Rutgers P, Hamers ARM, van Rhijn JA, Hoogenboom LAP (2006) Urine testing for designer steroids by liquid chromatography with androgen bioassay detection and electrospray quadrupole Time-of-Flight Mass spectrometry identification. Anal Chem 78(2):424-431
37. Nieschlag E, Behre HM (eds) (2004) Testosterone - action, deficiency, substitution. Cambridge University Press, Cambridge University Press, Cambridge, p 693-694
38. Numazawa M, Yamaguchi S (1999) Synthesis and structure-activity relationships of 6-phenyla-liphatic substituted C19 steroids having a 1, 4-diene, 4, 6-diene, or 1, 4, 6-triene structure as aromatase inhibitors. Steroids 64:187-196
39. Parr M, Kazlauskas R, Schlörer N, Opfermann G, Piper T, Schulze G, Schänzer W (2008) 6α-Methylandrostenedione: gas chromatographic mass spectrometric detection in doping control. Rapid Commun Mass Spectrom 22(3):321-329
40. Rodchenkov G, Sobolevsky T, Sizol V (2006) New designer anabolic steroids from internet. In: Schänzer et al (ed) Recent advances in doping analysis (14), Proceedings of the Manfred Donike workshop 24th cologne workshop on dope analysis 4th to 9th June 2006, pp 141-150
41. Schanzer W, Delahaut P, Geyer H, Machnik M, Horning S (1996) Long-term detection and identification of metandienone and stanozolol abuse in athletes by gas chromatography-high-resolution mass spectrometry. J Chromatogr B 687:93-108
42. Schrader Y, Thevis M, Schänzer W (2006) Quantitative determination of metabolic products of 19-norandrostenediol in human plasma using gas chromatography/mass spectrometry. Drug Metab Dispos 34(8):1328-1335
43. Schwarzel WC, Kruggel WG, Brodie HJ (1973) Studies on the mechanism of estrogen biosynthesis. VIII. The development of inhibitors of the enzyme system in human placenta. Endocrinology 92:866-880
44. Sekera MH, Ahrens BD, Chang Y-C, Starcevic B, Georgakopoulos C, Catlin DH (2005) Another designer steroid: discovery, synthesis, and detection of 'madol' in urine. Rapid Commun Mass Spectrom 19:781-784
45. Smith H (1965) Total Synthesis of steroid hormones. Trans NY Acad Sci 27(5):546
46. Thevis M (2007) Current role of LC-MS(/MS) in doping control. Anal Bioanal Chem 388 (7):1351-1358
47. Thevis M, Schänzer W (2005) Mass spectrometry in doping control analysis. Curr Org Chem 9 (9):825-848
48. Thevis M, Geyer H, Mareck U, Schänzer W (2005) Screening for unknown synthetic steroids in human urine by liquid chromatography-tandem mass spectrometry. J Mass Spectrom 40:955-962
49. Ueno K, Ohta G (1967) Investigations on steroids VII, derivatives of 17b-hydroxyandrostano[2, 3-c]furazan substituted at position 16. Chem Pharm Bull 15(4):518-522
50. Ungerleider S (2001) Faust's Gold: inside the East German doping machine, Thomas Dunne Books. St. Martin's Press, New York
51. USA Today (2007) http://www.usatoday.com/sports/balco-timeline.htm. sighted April 2008
52. USADA (2005) http://www.usantidoping.org/files/active/who/annual-report- 2005.pdf. sighted April 2008
53. Van Eenoo P, Delbeke FT (2006) Metabolism and excretion of anabolic steroids in doping control-new steroids and new insights. J Steroid Biochem Mol Biol 101:161-178
54. Von Weichert R, Steinbeck H, Elger W, Neumann F (1967) Wirkungen und Struktur neuer antiandogener Steroide. Arzneimittel-Forsch 17:1103-1116
55. WADA (2008); http://www.wada-ama.org/rtecontent/document/2008-List-En. pdf.
56. WADA (2009); http://www.wada-ama.org/rtecontent/document/2009-Prohibited- List-ENG-Final-20-Sept-08.pdf
57. WADA TD2003IDCR (2008); http://www.wada-ama.org/rtecontent/document/ criteria-1-2.pdf. sighted April 2008
58. Wolf ME, Chang H-H (1970) Synthesis and myotrophic-androgenic activity of 17b-hydroxy-5a-androst-8(14)-en-3-one derivatives. J Med Chem 14(5):967-968
59. Wolf ME, Zanati G (1969) Thia steroids. I. 2-Thia-A-nor-5α- androstan-17β-ol, an active androgen. J Med Chem 12:629-631
60. Wolf ME, Zanati G (1970) Preparation and androgenic activity of novel heterocyclic steroids. Experientia 26(10):115-116
61. Yuan X, Forman BM (2005) Detection of designer drugs. Nuclear Receptor Signaling 3: http:// www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1402217. sighted January 2009
62. Zanati G, Wolf ME (1971) Heterocyclic steroids. 2. Synthesis and androgenic activity of A-Ring oxaandrostanes. J Med Chem 14(10):958-961
63. Zanati G, Wolf ME (1972) Heterocyclic steroids. 4. Synthesis and androgenic activity of A-Ring homosteroids. J Med Chem 15(4):368-369